Ingalls & Snyder LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.9% in the 4th quarter, HoldingsChannel reports. The fund owned 623,083 shares of the biopharmaceutical company’s stock after selling 12,243 shares during the quarter. Pfizer accounts for approximately 1.4% of Ingalls & Snyder LLC’s investment portfolio, making the stock its 11th biggest holding. Ingalls & Snyder LLC’s holdings in Pfizer were worth $27,198,000 as of its most recent filing with the SEC.
Other institutional investors have also recently bought and sold shares of the company. Home Federal Bank of Tennessee raised its stake in Pfizer by 0.8% during the 4th quarter. Home Federal Bank of Tennessee now owns 29,695 shares of the biopharmaceutical company’s stock valued at $1,297,000 after acquiring an additional 249 shares during the last quarter. Advocacy Wealth Management Services LLC raised its stake in Pfizer by 48.2% during the 4th quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 258 shares during the last quarter. Viridian Ria LLC raised its stake in Pfizer by 0.9% during the 4th quarter. Viridian Ria LLC now owns 30,859 shares of the biopharmaceutical company’s stock valued at $1,327,000 after acquiring an additional 280 shares during the last quarter. Trust Co. of Oklahoma raised its stake in Pfizer by 4.4% during the 4th quarter. Trust Co. of Oklahoma now owns 7,079 shares of the biopharmaceutical company’s stock valued at $309,000 after acquiring an additional 300 shares during the last quarter. Finally, Capital City Trust Co. FL raised its stake in Pfizer by 6.9% during the 4th quarter. Capital City Trust Co. FL now owns 5,139 shares of the biopharmaceutical company’s stock valued at $224,000 after acquiring an additional 330 shares during the last quarter. 69.49% of the stock is owned by institutional investors and hedge funds.
PFE has been the subject of several analyst reports. Cantor Fitzgerald set a $53.00 price objective on Pfizer and gave the company a “buy” rating in a research note on Sunday, December 30th. Credit Suisse Group set a $45.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, January 1st. UBS Group downgraded Pfizer from a “buy” rating to a “neutral” rating in a research note on Wednesday, January 23rd. ValuEngine downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Finally, Zacks Investment Research downgraded Pfizer from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $45.61.
PFE opened at $39.61 on Friday. The company has a market capitalization of $234.57 billion, a P/E ratio of 13.20, a PEG ratio of 2.38 and a beta of 0.75. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.33 and a current ratio of 1.57. Pfizer Inc. has a 1-year low of $34.37 and a 1-year high of $46.47.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.01. The business had revenue of $13.98 billion for the quarter, compared to analysts’ expectations of $13.92 billion. Pfizer had a return on equity of 26.02% and a net margin of 20.79%. The company’s revenue was up 2.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.62 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.86 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 10th will be issued a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.64%. Pfizer’s dividend payout ratio is currently 48.00%.
In other Pfizer news, insider Mikael Dolsten sold 149,553 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $43.55, for a total transaction of $6,513,033.15. Following the sale, the insider now owns 390,097 shares in the company, valued at approximately $16,988,724.35. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Rady A. Johnson sold 8,700 shares of the stock in a transaction on Friday, March 15th. The shares were sold at an average price of $41.13, for a total value of $357,831.00. Following the sale, the insider now owns 59,797 shares in the company, valued at approximately $2,459,450.61. The disclosure for this sale can be found here. In the last 90 days, insiders sold 332,526 shares of company stock worth $14,346,539. Insiders own 0.09% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Ingalls & Snyder LLC Has $27.20 Million Stake in Pfizer Inc. (PFE)” was published by Highlight Press and is the property of of Highlight Press. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://highlightpress.com/2019/04/26/ingalls-snyder-llc-has-27-20-million-stake-in-pfizer-inc-pfe.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
See Also: How to Use the New Google Finance Tool
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.